Synthetic Biology

Synthetic Biology

Dark abstract geometric shapes creating a layered pattern with gradient shading.

Synthetic biology has the potential to transform every sector, from construction to pharmaceuticals, but it's still seen as hard to commercialise. With the right team, it doesn't have to be. Our experts help you cut through complexity, protect your innovation and build an intellectual property (IP) strategy that delivers commercial results.

Protecting and commercialising synthetic biology depends on making the right decisions early. From when and how to disclose to whether patents or trade secrets are the better option, your IP strategy will shape how your business grows.

These decisions affect more than protection alone. They influence investor confidence, market access and your ability to secure and retain a competitive edge. If ownership isn't clearly defined, especially when collaboration runs through multiple layers of the synbio stack, that risk only increases.

You also need to be confident that your product can be marketed in your target territories. Regulatory frameworks vary significantly between countries, and what's permitted in one may be restricted or banned in another.

Our experienced interdisciplinary team combines legal, scientific, and commercial expertise to help you make the right calls, protecting your innovation and putting the right structure in place to support your strategy.

Want to discuss the protection and commercialisation of your synthetic biology innovation? Contact our team.

How We Help Protect and Commercialise Your Synthetic Biology Innovation

We understand synthetic biology. Our team has the academic background, technical expertise, and client experience to help you develop, protect, and commercialise your innovations.

We're also embedded in the synbio community. We hold board and committee positions, mentor accelerators and incubators around the world, and run networks like Women in Synthetic Biology (in conjunction with SynBioBeta and the Industrial Biotechnology Innovation Centre) and BioAmass across the UK.

Here's how we support synthetic biology companies in practice:

Bespoke interdisciplinary teams

Synthetic biology spans molecular cloning, cell biology, microbiology, AI, engineering, and chemistry. Just as your technology brings together multiple disciplines, so does our team.

We build bespoke teams combining patent attorneys with backgrounds not only in molecular microbiology but also in bioreactors, machine learning, and AI. Your team will also include IP solicitors who advise on licensing, partnerships, and commercial contracts, so your legal and technical strategy is fully aligned.

Commercially focused advice across sectors

Synthetic biology is a true platform technology. Many synbio companies identify as foodtech, agritech, cleantech, construction materials, therapeutics, or consumer brands. The technology rarely fits into a single category.

That's why our sector teams include synthetic biology specialists who understand the nuances of your market and provide commercially focused advice tailored to:

Support at every stage

  • Early-stage companies. If you're coming out of academia, we help shape your commercial offering and make you investment-ready. We also specialise in supporting university spinouts and scientist-founders. If you're just starting your journey, you may want to take a look at our IP Primer for Scientist-Founders.
  • Scaling businesses. If you're planning to scale, we help align your IP with growth plans, partnerships, and new markets.
  • Established companies. We ensure your IP supports strategic direction and helps maximise market share and shareholder value.
  • Investors. We assess the IP and business plans of potential investees to verify their claims, reduce risk, and maximise your return on investment.

Related News

Can space agriculture tackle the food crisis and how is IP enforced in space?

Can space agriculture tackle the food crisis and how is IP enforced in space?

Potter Clarkson launches landmark patent landscape analysis of the SynBio revolution

Potter Clarkson launches landmark patent landscape analysis of the SynBio revolution

Can CRISPR and RNAi help us develop new and more sustainable fruits and vegetables?

Can CRISPR and RNAi help us develop new and more sustainable fruits and vegetables?

The Cali Fund and DSI: What life sciences and biotech companies need to know now

The Cali Fund and DSI: What life sciences and biotech companies need to know now

Potter Clarkson supports launch of groundbreaking Carbon-Loop Biomanufacturing Hub

Potter Clarkson supports launch of groundbreaking Carbon-Loop Biomanufacturing Hub

A decisive moment for engineering biology: UK must act now to realise benefits

A decisive moment for engineering biology: UK must act now to realise benefits

Alt-chocolate: How confectioners are finding more sustainable ways of producing chocolate

Alt-chocolate: How confectioners are finding more sustainable ways of producing chocolate

Channelling innovation in greentech: UK IPO report spotlights industry leaders

Channelling innovation in greentech: UK IPO report spotlights industry leaders

Get in Touch with Our Synthetic Biology Team

Mark Didmon
Edwina FitzHugh
Sara Holland
Dave Holt
Jason Teng

Want to discuss the protection and commercialisation of your synthetic biology innovation? Fill in the form and our team will be in touch soon.

Thank you.
Your details have been submitted.
Oops! Something went wrong while submitting the form.